Johnson & Johnson (JNJ) Monday said it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for icotrokinra for the treatment of individuals aged 12 years and older with plaque psoriasis.
The application included data from four pivotal Phase 3 studies conducted as part of the ICONIC clinical development program, including ICONIC-LEAD, ICONIC-TOTAL and ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2. Treatment with icotrokinra met all primary goals across the studies.
The company has also initiated the Phase 3 ICONIC-ASCEND study, to show the superiority of an oral pill, icotrokinra, compared to an injectable ustekinumab.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.